|
Lannett Company Receives FDA Approval for Pilocarpine HCI Tablets 7.5 mg Strength.
Business Wire
|
May 8, 2009
|
COPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
PHILADELPHIA -- Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic pharmaceuticals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDAs) for Pilocarpine HCI tablets, 7.5 mg, the generic equivalent of Salagen[R], marketed by Eisai Pharmaceuticals. Lannett previously received and currently markets Pilocarpine HCI tablets, in the 5 mg strength. According to Wolters Kluwer, sales in 2008 of both generic and brand Pilocarpine HCI 7.5 mg tablets were $2.5 million at ...
Find more facts and information related to the
article "Lannett Company Receives FDA Approval for ..."